- Home
- AKBA vs SB Comparison
AKBA vs SB Comparison
Compare AKBA & SB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- SB
- Stock Information
- Founded
- AKBA 2007
- SB 2007
- Country
- AKBA United States
- SB Monaco
- Employees
- AKBA N/A
- SB N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- SB Marine Transportation
- Sector
- AKBA Health Care
- SB Consumer Discretionary
- Exchange
- AKBA Nasdaq
- SB Nasdaq
- Market Cap
- AKBA 336.2M
- SB 374.8M
- IPO Year
- AKBA 2014
- SB 2008
- Fundamental
- Price
- AKBA $1.83
- SB $3.50
- Analyst Decision
- AKBA Strong Buy
- SB Strong Buy
- Analyst Count
- AKBA 1
- SB 1
- Target Price
- AKBA $7.50
- SB $6.00
- AVG Volume (30 Days)
- AKBA 2.4M
- SB 826.3K
- Earning Date
- AKBA 11-07-2024
- SB 02-10-2025
- Dividend Yield
- AKBA N/A
- SB 5.70%
- EPS Growth
- AKBA N/A
- SB 35.10
- EPS
- AKBA N/A
- SB 0.90
- Revenue
- AKBA $169,879,000.00
- SB $318,430,000.00
- Revenue This Year
- AKBA N/A
- SB $6.67
- Revenue Next Year
- AKBA $30.85
- SB N/A
- P/E Ratio
- AKBA N/A
- SB $3.91
- Revenue Growth
- AKBA N/A
- SB 10.27
- 52 Week Low
- AKBA $0.80
- SB $3.40
- 52 Week High
- AKBA $2.48
- SB $6.33
- Technical
- Relative Strength Index (RSI)
- AKBA 46.55
- SB 27.21
- Support Level
- AKBA $1.74
- SB $3.40
- Resistance Level
- AKBA $1.90
- SB $3.69
- Average True Range (ATR)
- AKBA 0.09
- SB 0.15
- MACD
- AKBA -0.03
- SB -0.02
- Stochastic Oscillator
- AKBA 20.93
- SB 14.71
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About SB Safe Bulkers Inc ($0.001 par value)
Safe Bulkers Inc is an international provider of marine drybulk transportation services, transporting bulk cargoes, particularly coal, grain and iron ore, along international shipping routes for consumers of marine drybulk transportation services. The company employs its vessels on both period time charters and spot time charters, according to the assessment of market conditions, with consumers of marine drybulk transportation services.